the MitraClip system has provided an additional armamentarium to the treatment of mitral valve disease.

References

Commentary: Trends in mitral valve interventions: The good, the bad, and the ugly

Davide Pacini, MD, PhD, and Giacomo Murana, MD, PhD

After the burden of transcatheter aortic valve implantation, mitral valve regurgitation has become the most common valve-related disease requiring surgical correction.1 Two main innovations have dramatically changed the landscape of mitral valve intervention. The first, introduced in 1983, was the so-called French correction that represented the dawn of mitral repair. The second was the advent of the MitraClip device (Abbott Laboratories, Abbott Park, Ill) in 2013, leading to percutaneous mitral valve interventions that allow us to treat sicker patients. The evolution of this new concepts became an evident recommendation of the latest American Heart Association/American College of Cardiology guidelines2 where mitral valve repair is the preferred technique when a successful and durable repair can be accomplished despite symptoms, age, or comorbidities and a MitraClip is indicated (only in primary mitral regurgitation) in favorable anatomy when patients have prohibitive surgical risk.

Zhou and colleagues’ elucidate the trends and outcomes of 656,030 mitral valve interventions in 44 states participating in the Nationwide Inpatient Sample administrative database. They analyzed the trends in patient characteristics, focusing on comorbidities and, thus, on the preoperative risk. During the past 2 decades, the number of replacements decreased significantly by 5.6% per year, whereas repair increased by 8.4% per year and MitraClip

From the Cardiac Surgery Unit, Cardio-Thoraco-Vascular Department, S. Orsola Hospital, University of Bologna, Bologna, Italy.

Disclosures: Authors have nothing to disclose with regard to commercial support.

Received for publication Jan 15, 2020; accepted for publication Jan 24, 2020; available ahead of print Feb 4, 2020.

Address for reprints: Davide Pacini, MD, PhD, Cardiac Surgery Unit, Cardio-Thoraco-Vascular Department, S. Orsola Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy (E-mail: davide.pacini@aosp.bo.it).

0022-5223/$36.00
Copyright © 2020 by The American Association for Thoracic Surgery
https://doi.org/10.1016/j.jtcvs.2020.01.049

The next frontier in mitral valve interventions: The good, the bad, and the ugly.

CENTRAL MESSAGE
Mitral valve interventions are associated with excellent surgical results making them the next frontier for percutaneous approaches.
procedures increased by 84.4% annually from 2013 to 2016. Despite comorbidities increased throughout the study for all groups, in-hospital mortality decreased from 8.5% to 3.7% for all interventions, with MitraClip having the most substantial decrease from 3.6% to 1.5%. The results depict how mitral valve interventions were associated with improved outcomes despite being applied to an increasingly sicker population. However, the main limitation of the current nonrandomized study was the lack of patient selection among treatments and collection of data from hospital discharge databases that are missing International Classification of Diseases diagnosis code (necessary to distinguish between primary and secondary mitral regurgitation), supply utilization (necessary to identify mini-thoracotomy or robotic surgery), and other clinical information such as regurgitation percentage and left ventricle dilation. Nevertheless, the possibility to treat patients in Heart Valve Centers of Excellence where successful outcomes are obtained across the spectrum of mitral valve pathologies with valve repair, replacement, or using catheter-based interventions mitigates these relevant drawbacks.4

The good news is that mitral valve interventions are effectively mostly reparative, are associated with improved outcomes despite being applied to an increasingly sicker population, and the possibility of a percutaneous intervention is a reality. The bad is that MitraClip device use is still limited on patient selection and robust midterm results are still lacking. The ugly is that MitraClip represents the only Food and Drug Administration-approved percutaneous mitral valve repair device and none of the actual devices provide the same treatment as conventional surgery.

References

Commentary: What is now proved was once only imagined

Vito Domenico Bruno, MD, PhD

Mitral valve (MV) surgery has been a constantly evolving field since the beginning. From the first surgical series to these days, innovations1-3 have been introduced in a continuous effort to improve the results and therefore enhance not only the life expectancy, but also the quality of life of the patients. Multiple methods of treatment have been introduced over the years and different techniques and surgical approaches have been studied in numerous retrospective and prospective studies. Nowadays, we are...